PF 07202954
Alternative Names: PF-07202954Latest Information Update: 09 Nov 2022
At a glance
- Originator Pfizer
- Class Hepatoprotectants
- Mechanism of Action Diacylglycerol O-acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatic fibrosis; Non-alcoholic steatohepatitis
Most Recent Events
- 09 Nov 2022 Discontinued - Phase-I for Hepatic fibrosis (In volunteers) in USA (PO) (Pfizer pipeline, November 2022)
- 09 Nov 2022 Discontinued - Phase-I for Non-alcoholic steatohepatitis (In volunteers) in USA (PO) (Pfizer pipeline, November 2022)
- 17 Sep 2021 Pfizer completes a phase I trial for Non-alcoholic steatohepatitis and Liver fibrosis (In volunteers) (PO) (NCT04857437)